Stay updated on Ruxolitinib in COVID Cytokine Storm Clinical Trial
Sign up to get notified when there's something new on the Ruxolitinib in COVID Cytokine Storm Clinical Trial page.

Latest updates to the Ruxolitinib in COVID Cytokine Storm Clinical Trial page
- Check5 days agoChange DetectedThe Revision label on the page was updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check34 days agoChange DetectedRevision: v3.4.2 is now displayed on the page. The previous government funding lapse notice has been removed, and core study content remains unchanged.SummaryDifference0.3%

- Check41 days agoChange DetectedA site-wide Notice about a lapse in government funding and updated operating status was added, and the page revision indicator changed from v3.4.0 to v3.4.1.SummaryDifference0.3%

- Check48 days agoChange DetectedThe changes are minor UI and metadata updates (Show glossary toggle, Last Update Submitted that Met QC Criteria wording, No FEAR Act data notice, and Revision: v3.4.0) and do not affect core study information or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check62 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check84 days agoChange DetectedNew location listings were added across multiple countries and regions, and several existing locations were removed. A revision tag Revision: v3.3.3 is shown.SummaryDifference2%

Stay in the know with updates to Ruxolitinib in COVID Cytokine Storm Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ruxolitinib in COVID Cytokine Storm Clinical Trial page.